162 related articles for article (PubMed ID: 24256051)
1. Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China.
Wang ZM; Xiang YT; An FR; Correll CU; Ungvari GS; Wang CY; Lai KY; Bo QJ; Li Y; Zhong BL; Chiu HF
Perspect Psychiatr Care; 2014 Oct; 50(4):257-63. PubMed ID: 24256051
[TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
An FR; Yang R; Wang ZM; Ungvari GS; Ng CH; Chiu HF; Wu PP; Jin X; Li L; Lok GK; Xiang YT
Compr Psychiatry; 2016 Nov; 71():71-76. PubMed ID: 27639124
[TBL] [Abstract][Full Text] [Related]
3. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications.
Alosaimi FD; Fallata EO; Abalhassan M; Alhabbad A; Alzain N; Alhaddad B; Alassiry MZ
Int J Psychiatry Clin Pract; 2018 Nov; 22(4):274-281. PubMed ID: 29334291
[TBL] [Abstract][Full Text] [Related]
5. [Hyperprolactinemia in mentally ill patients].
Carvalho MM; Góis C
Acta Med Port; 2011; 24(6):1005-12. PubMed ID: 22713195
[TBL] [Abstract][Full Text] [Related]
6. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
7. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
Bret P; Bonnet F; Bret MC; Jaffré A
Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
[TBL] [Abstract][Full Text] [Related]
8. Clinical Management of Antipsychotic-Induced Hyperprolactinemia.
Wong-Anuchit C
Perspect Psychiatr Care; 2016 Apr; 52(2):145-52. PubMed ID: 25772527
[TBL] [Abstract][Full Text] [Related]
9. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
10. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012).
Li Q; Xiang YT; Su YA; Shu L; Yu X; Correll CU; Ungvari GS; Chiu HF; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM; Kane JM
Schizophr Res; 2015 Oct; 168(1-2):523-9. PubMed ID: 26277534
[TBL] [Abstract][Full Text] [Related]
11. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.
Bushe C; Yeomans D; Floyd T; Smith SM
J Psychopharmacol; 2008 Mar; 22(2 Suppl):56-62. PubMed ID: 18477621
[TBL] [Abstract][Full Text] [Related]
12. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia associated with psychotropics--a review.
Madhusoodanan S; Parida S; Jimenez C
Hum Psychopharmacol; 2010; 25(4):281-97. PubMed ID: 20521318
[TBL] [Abstract][Full Text] [Related]
14. Frequency of physical restraint and its associations with demographic and clinical characteristics in a Chinese psychiatric institution.
Zhu XM; Xiang YT; Zhou JS; Gou L; Himelhoch S; Ungvari GS; Chiu HF; Lai KY; Wang XP
Perspect Psychiatr Care; 2014 Oct; 50(4):251-6. PubMed ID: 24308920
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
Byerly M; Suppes T; Tran QV; Baker RA
J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
[TBL] [Abstract][Full Text] [Related]
16. Use of atypical antipsychotic medications in adolescent psychiatric inpatients: a comparison with inpatients who did not receive antipsychotic medications during their stay.
Pogge DL; Young K; Insalaco B; Harvey PD
Int J Clin Pract; 2007 Jun; 61(6):896-902. PubMed ID: 17504351
[TBL] [Abstract][Full Text] [Related]
17. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
[TBL] [Abstract][Full Text] [Related]
18. A review of the association between antipsychotic use and hyperprolactinaemia.
Bushe C; Shaw M; Peveler RC
J Psychopharmacol; 2008 Mar; 22(2 Suppl):46-55. PubMed ID: 18477620
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Bushe C; Shaw M
J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment.
Montgomery J; Winterbottom E; Jessani M; Kohegyi E; Fulmer J; Seamonds B; Josiassen RC
J Clin Psychiatry; 2004 Nov; 65(11):1491-8. PubMed ID: 15554761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
